Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMpALA: Avelumab and Aspirin in Triple-Negative Breast Cancer
NCT04188119Phase 2Withdrawn
- Sponsor
- The Christie
- Start
- Dec 2023
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, randomised, open-label trial of aspirin in triple-negative breast cancer (TNBC) (2 arms), sponsored by The Christie. Primary endpoint: Mean combined gene expression of COX-2 tumour-promoting genes at 7 weeks. Planned start Dec 2023; status: withdrawn.
02
Drugs
aspirin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04188119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188119.